Pharming Group (NASDAQ:PHAR) Shares Gap Up - Still a Buy?

Key Points

• Pharming Group's shares opened at $15.19 after closing at $13.51, reflecting a more than 10% increase in trading activity with transactions of 892 shares.
• The company reported earnings of $0.06 EPS for its last quarter, exceeding estimates, with revenues reaching $93.20 million against an expected $70.36 million.
• Institutional interest is rising, as EverSource Wealth Advisors LLC recently acquired nearly 3,000 shares of Pharming Group stock, valued at approximately $32,000.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $13.51, but opened at $15.19. Pharming Group shares last traded at $14.91, with a volume of 892 shares changing hands.

Pharming Group Stock Up 10.2%

The firm's fifty day moving average price is $11.92 and its two-hundred day moving average price is $10.29. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -114.54 and a beta of 0.05. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.79 and a quick ratio of 2.07.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,979 shares of the company's stock, valued at approximately $32,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.